Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

(2020) Christina Friese et al.   Scientific Reports

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

(2020) Amod Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

1052P Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer

(2020) K. Ritthipichai et al.   ANNALS OF ONCOLOGY

Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma

(2020) Chao Wang et al.   Journal of Bone Oncology

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

(2019) Amod Sarnaik et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

(2019) Amir A. Jazaeri et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

(2019) Matthew B. Dong et al.   CELL

Clinical lessons learned from the first leg of the CAR T cell journey

(2019) Robbie G. Majzner et al.   NATURE MEDICINE

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

(2018) Nikolaos Zacharakis et al.   NATURE MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

(2018) Eric Shifrut et al.   CELL

Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation

(2018) Tom B Davidson et al.   CLINICAL CANCER RESEARCH

T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy

(2017) Robert Sackstein et al.   LABORATORY INVESTIGATION

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

(2017) Marie-Andrée Forget et al.   Frontiers in Immunology

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

(2016) MacLean Hall et al.   Journal for ImmunoTherapy of Cancer

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

(2015) Sanja Stevanović et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

(2015) M. E. Mikucki et al.   Nature Communications

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma

(2014) Rikke Andersen et al.   Journal for ImmunoTherapy of Cancer

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

(2013) D Bedognetti et al.   BRITISH JOURNAL OF CANCER

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

(2013) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

(2012) X. Yao et al.   BLOOD

Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma

(2012) Richard Wu et al.   CANCER JOURNAL

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

(2012) Eva Ellebaek et al.   Journal of Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells

(2011) I. Jedema et al.   HAEMATOLOGICA

Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution

(2011) M. Donia et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2

(2008) Bianca Heemskerk et al.   HUMAN GENE THERAPY

Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

(2008) Khoi Q. Tran et al.   JOURNAL OF IMMUNOTHERAPY